靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段早期临床1期 |
首次获批国家/地区- |
首次获批日期- |
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether AcNK-Sup003 cell injection is safe and effective in the treatment of elapsed or refractory B-cell non-Hodgkin's lymphoma.
100 项与 SUPERMAB (BEIJING) BIOTECH CO., LTD. 相关的临床结果
0 项与 SUPERMAB (BEIJING) BIOTECH CO., LTD. 相关的专利(医药)
100 项与 SUPERMAB (BEIJING) BIOTECH CO., LTD. 相关的药物交易
100 项与 SUPERMAB (BEIJING) BIOTECH CO., LTD. 相关的转化医学